- Home
- OTLK vs NOMA Comparison
OTLK vs NOMA Comparison
Compare OTLK & NOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | NOMA |
|---|---|---|
| Founded | 2010 | 2023 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 115.0M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | NOMA |
|---|---|---|
| Price | $0.56 | $4.02 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 8.1M | 55.1K |
| Earning Date | 02-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,413,535.00 | $885,694.00 |
| Revenue This Year | $2,048.59 | N/A |
| Revenue Next Year | $142.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $4.08 |
| 52 Week High | $3.39 | $57.70 |
Technical Indicators
Market Signals| Indicator | OTLK | NOMA |
|---|---|---|
| Relative Strength Index (RSI) | 22.80 | N/A |
| Support Level | $1.78 | N/A |
| Resistance Level | $2.03 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 2.64 | 0.00 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About NOMA NOMADAR Corp.
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through innovative technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes.